Eisai clinical trial pipeline

4 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 1 with a minor change only.

1. Notable

   Potential Drug-Drug Interactions of E2086 in Healthy Participants

   Recruitment opened

   Eisai Inc.·Phase 1· NCT07766369· Registry history of NCT07766369 on ClinicalTrials.gov (opens the registry)

   Oct 6, 2026

2. Notable

   Post Authorization Registry Study of Participants Treated With…Post Authorization Registry Study of Participants Treated With LEQEMBI

   Recruitment opened

   Also in this update: Trial sites expanded: 11 → 17 locations

   Eisai Limited·Not specified· NCT07762092· Registry history of NCT07762092 on ClinicalTrials.gov (opens the registry)

   Sep 22, 2026

3. Notable

   Clarity AD · Confirm Safety and Efficacy of Lecanemab · Early…Clarity AD · Confirm Safety and Efficacy of Lecanemab · Early Alzheimer's Disease

   Primary and study completion moved earlier from Jun 30, 2029 to Dec 31, 2026

   Eisai Inc.·Phase 3· NCT03887455· Registry history of NCT03887455 on ClinicalTrials.gov (opens the registry)

   Oct 6, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.